Core Insights - The company reported a decline in key financial metrics for the year 2024, with revenue at €216.8 million, a decrease of 1.4% compared to 2023, and a net profit attributable to Group shareholders of €36.2 million, down 23.0% [2][4]. Financial Performance - Revenue for 2024 was €216.8 million, down from €219.7 million in 2023, reflecting a decrease of €3.0 million or 1.4% [2][4]. - Current Operating Income (COI) fell to €45.1 million, a decline of 19.2% from €55.8 million in 2023 [2][4]. - Net profit attributable to the Group decreased to €36.2 million, down €10.8 million or 23.0% from the previous year [2][4]. Division Analysis - Pharmagest Division: COI decreased to €30.7 million, down 16.4% from €36.7 million in 2023, primarily due to lower sales in the first half of the year [3][7]. - Axigate Link Division: Maintained a high profitability rate with COI at €10.2 million, a slight decrease of 2.3% from €10.4 million in 2023 [3][9]. - e-Connect Division: COI dropped to €4.8 million, down 28.0% from €6.7 million in 2023, attributed to lower sales [3][10]. - Medical Solutions Division: COI was €0.2 million, a significant decline of 92.0% from €2.2 million in 2023, as the division transitioned to new software solutions [3][12]. - Fintech Division: Experienced a deterioration in operating income, with COI at -€0.8 million, reflecting a significant decline of 73.4% in the second half of the year [3][14]. Strategic Outlook - The company aims for a return to revenue growth of close to 10% by the end of 2025, supported by investments in new solutions integrating artificial intelligence and cloud services [4][18]. - The strategy includes maintaining external growth initiatives in France and Europe while focusing on R&D and infrastructure investments [4][18]. Dividend Proposal - The Board of Directors proposed a gross dividend of €1.25 per share for fiscal 2024, to be discussed at the Annual General Meeting on June 25, 2025 [4][17]. Financial Health - The company reported a strong financial surplus of €79.5 million, indicating solid balance sheet structure despite the decline in profits [4][24].
Equasens: 2024 annual results